The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

Bibliographic Details
Main Authors: Goldstein, D, Spry, N, Cummins, M M, Brown, C, van Hazel, G A, Carroll, S, Selva-Nayagam, S, Borg, M, Ackland, S P, Wratten, C, Shapiro, J, Porter, I W T, Hruby, G, Horvath, L, Bydder, S, Underhill, C, Harvey, J, Gebski, V J
Format: Online
Language:English
Published: Nature Publishing Group 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251866/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251866/

Similar Items